KRAS and leukemia: For instance, HSCs acquiring Runx1::Runx1T1 gain a competitive advantage, which leads to an expansion in the number of HSCs, thereby increasing the pool of cells capable of acquiring additional mutations like Kras. Ultimately, this promotes the development of leukemia and mimics the disease phenotype in mice.